Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.62 |
| ▸ | NPC1 | O15118 | 3/20 | 0.61 |
| ▸ | RAB9A | P51151 | 3/20 | 0.61 |
| ▸ | CA1 | P00915 | 3/20 | 0.49 |
| ▸ | CA2 | P00918 | 3/20 | 0.49 |
| ▸ | CA7 | P43166 | 3/20 | 0.49 |
| ▸ | CA9 | Q16790 | 2/20 | 0.49 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.47 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7393652 | 0.89 | MEN1 (0.76) | SMN1; SMN2CYP2C19MEN1KMT2ANPSR1 | |
| SCHEMBL3970912 | 0.89 | MEN1 (0.76) | SMN1; SMN2CYP2C19MEN1KMT2ANPSR1 | |
| SCHEMBL379160 | 0.89 | MEN1 (0.76) | SMN1; SMN2CYP2C19MEN1KMT2ANPSR1 | |
| SCHEMBL4814264 | 0.89 | MEN1 (0.76) | SMN1; SMN2CYP2C19MEN1KMT2ANPSR1 | |
| SCHEMBL15011579 | 0.87 | MEN1 (0.73) | SMN1; SMN2CYP2C19MEN1KMT2ANPSR1 | |
| Bicarbonate SCHEMBL4357688 | 0.87 | MEN1 (0.73) | SMN1; SMN2CYP2C19MEN1KMT2ANPSR1 | |
| SCHEMBL8010989 | 0.86 | SMN1; SMN2 (0.68) | SMN1; SMN2CYP2C19MEN1KMT2ANPSR1 | |
| SCHEMBL27630267 | 0.84 | MEN1 (0.66) | SMN1; SMN2CYP2C19MEN1KMT2ANPSR1 | |
| SCHEMBL1675680 | 0.84 | MEN1 (0.66) | SMN1; SMN2CYP2C19MEN1KMT2ANPSR1 | |
| SCHEMBL16611411 | 0.84 | MEN1 (0.69) | SMN1; SMN2CYP2C19MEN1KMT2ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3419972-B1 | GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2023-07-26 | — | — | EP | disclosed |
| US-11612599-B2 | Glycosidase inhibitors | ASCENEURON SA (CH) | 2023-03-28 | — | — | US | disclosed |
| EP-3419971-B1 | GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2022-04-20 | — | — | EP | disclosed |
| US-20210186958-A1 | GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2021-06-24 | — | — | US | disclosed |
| US-10556902-B2 | Glycosidase inhibitors | ASCENEURON SA (CH) | 2020-02-11 | — | — | US | disclosed |
| US-20190055239-A1 | GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2019-02-21 | — | — | US | disclosed |
| EP-3419972-A1 | GLYCOSIDASE INHIBITORS | Asceneuron SA (CH) | 2019-01-02 | — | — | EP | disclosed |
| EP-3419971-A1 | GLYCOSIDASE INHIBITORS | Asceneuron SA (CH) | 2019-01-02 | — | — | EP | disclosed |
| WO-2017144639-A1 | GLYCOSIDASE INHIBITORS | ASCENEURON S. A. (CH) | 2017-08-31 | — | — | WO | disclosed |
| WO-2017144633-A1 | GLYCOSIDASE INHIBITORS | ASCENEURON S. A. (CH) | 2017-08-31 | — | — | WO | disclosed |
| US-20110059984-A1 | HETEROCYCLES USEFUL AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-10 | — | — | US | disclosed |
| US-20110059984-A1 | HETEROCYCLES USEFUL AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-10 | — | — | US | disclosed |
| US-7880008-B2 | Such as 4-(-1,2,4-thiadiazol-3-yl)piperazine-1-carboxylate and 4-(thiazol-2-yl)piperazine-1-carboxylate derivatives; antiinflammatory, anticarcinogenic, antiepileptic, antiarthritic, and analgesic agents; neurodegenerative and muscular disorders; sodium and calcium channel modulators; diabetes, headaches | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-02-01 | — | — | US | disclosed |
| US-7880008-B2 | Such as 4-(-1,2,4-thiadiazol-3-yl)piperazine-1-carboxylate and 4-(thiazol-2-yl)piperazine-1-carboxylate derivatives; antiinflammatory, anticarcinogenic, antiepileptic, antiarthritic, and analgesic agents; neurodegenerative and muscular disorders; sodium and calcium channel modulators; diabetes, headaches | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-02-01 | — | — | US | disclosed |
| US-7880008-B2 | Such as 4-(-1,2,4-thiadiazol-3-yl)piperazine-1-carboxylate and 4-(thiazol-2-yl)piperazine-1-carboxylate derivatives; antiinflammatory, anticarcinogenic, antiepileptic, antiarthritic, and analgesic agents; neurodegenerative and muscular disorders; sodium and calcium channel modulators; diabetes, headaches | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-02-01 | — | — | US | disclosed |
| US-20080255147-A1 | Heterocycles useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2008-10-16 | — | — | US | disclosed |
| US-20080255147-A1 | Heterocycles useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2008-10-16 | — | — | US | disclosed |
| US-20080255147-A1 | Heterocycles useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2008-10-16 | — | — | US | disclosed |
| EP-1904491-A2 | HETEROCYCLES USEFUL AS MODULATORS OF ION CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2008-04-02 | — | — | EP | disclosed |
| WO-2006130493-A2 | HETEROCYCLES USEFUL AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11612599-B2 | Glycosidase inhibitors | ENGASE, GAA, GLA | SMN1; SMN2 1307/4885CYP2C19 1942/4885MEN1 3407/4885 |
| US-10556902-B2 | Glycosidase inhibitors | ENGASE, GAA, GLA | SMN1; SMN2 1296/4885CYP2C19 2084/4885MEN1 3451/4885 |
| US-20210186958-A1 | GLYCOSIDASE INHIBITORS | ENGASE, GAA, GLA | SMN1; SMN2 1307/4885CYP2C19 1942/4885MEN1 3407/4885 |
| US-20080255147-A1 | Heterocycles useful as modulators of ion channels | KCNJ2, TRPV1, KCNJ1 | SMN1; SMN2 1136/4885CYP2C19 2006/4885MEN1 1502/4885 |
| US-20190055239-A1 | GLYCOSIDASE INHIBITORS | ENGASE, GAA, GLA | SMN1; SMN2 1296/4885CYP2C19 2084/4885MEN1 3451/4885 |
| US-20110059984-A1 | HETEROCYCLES USEFUL AS MODULATORS OF ION CHANNELS | KCNJ2, TRPV1, KCNJ1 | SMN1; SMN2 1136/4885CYP2C19 2006/4885MEN1 1502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.